Primary Infection With Zidovudine-Resistant HIV

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Primary Infection With Zidovudine-Resistant HIV

New England Journal of Medicine (10/07/93) Vol. 329, No. 15, P. 1123 (Hermans, P. et al.)

Hermans et al. challenge the conclusions of Erice et al., who described an HIV-positive patient with a primary infection that showed resistance to zidovudine. Erice et al. suggested that isolates that are resistant to nucleoside analog drugs are associated with a higher virulence or modified immune response. After their subsequent study of the isolates of five acute HIV patients with resistant strains, Hermans et al. clinically did not observe any longer duration or greater severity of symptoms in the subjects. Nor could they find any evidence to support the conclusions of Erice et al. Hermans et al. reported that the frequency of such primary zidovudine- resistant strains is still unknown, but that they are probably more frequent than previously thought. The researchers said that these findings have implications for clinical trial design.

931026
AD931937

Copyright © 1993 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.